What are cord blood plasma and AFP?
Cord blood plasma is the liquid portion of blood collected from the umbilical cord and placenta after a healthy birth, once the cells are separated out. It comes from the very start of life, which is exactly why researchers care about it: it carries the mix of proteins, growth factors, and signaling molecules the body uses when it is growing and repairing at full capacity.
Alpha-fetoprotein, or AFP, is one specific protein from that early-life toolkit. It is abundant in the developing fetus and in cord blood, then drops to trace levels in adults. A molecule strongly tied to early development that largely disappears later in life is an interesting molecule, and AFP can be studied as part of whole cord blood plasma or as an isolated factor in its own right.
How are they thought to work?
AFP's story is immune regulation. A 2022 review in Trends in Immunology describes it as an immunomodulator: rather than stimulating or suppressing immunity across the board, it appears to steer specific immune cell populations, limiting the activity of natural killer cells, monocytes, and dendritic cells, and shifting dendritic cells toward promoting regulatory T cells. Balance rather than blunt force, which is the behavior you want in autoimmune territory.
Cord blood plasma as a whole borrows its rationale from the wider young-plasma field: the idea that circulating factors present early in life carry signals that support tissue and cellular function, and that reintroducing them could influence age-related changes. That rationale rests largely on animal work, and the human trials testing it directly are only beginning.
Why they matter in regenerative medicine
Two threads make this corner of biologics compelling. First, the immune angle: most immune-suppressing drugs work like dimmer switches on the whole system, so a protein that nudges the system toward regulation instead is a genuinely different idea, which is why reviewers discuss AFP for autoimmune conditions. Second, the aging angle: the young-plasma hypothesis is one of the boldest ideas in longevity research, and cord blood plasma is its most practical source material, collected without harm at birth from tissue that would be discarded.
What they are being explored for
The research follows the biology. AFP is discussed for autoimmune disease because of its regulatory behavior, and it doubles as a target in oncology, where a completed Phase 1 trial engineered patients' own T cells to recognize AFP in advanced liver cancer. Cord blood plasma sits in the longevity and healthy-aging conversation, where a Phase 1 randomized, double-blind, placebo-controlled pilot (64 participants) tested cord blood and plasma in pre-frail adults aged 55 and over, tracking physical performance, grip strength, quality of life, and a panel of aging biomarkers.
In practice, birth-tissue biologics including cord blood plasma and AFP are used in regenerative protocols abroad, typically alongside cell therapies rather than alone, under physician direction.
What clients notice in practice
What people report after biologics protocols that include cord blood plasma or AFP, labeled honestly as experience rather than trial evidence, tends toward the systemic and subtle: better energy and recovery, calmer inflammatory symptoms, a general sense of resilience over the following weeks. These preparations are usually given alongside other treatments, which makes single-ingredient credit even harder to assign than usual, and nobody runs their own biomarker panel before and after.
That is the honest shape of anecdote in this space: real experiences, low attribution confidence, and a trial base that is only starting to catch up.
The pros and the cons
What's promising
- AFP's immune-regulating behavior is documented and mechanistically distinctive: balance, not blunt suppression.
- The young-plasma rationale has striking animal foundations, including the parabiosis cognition findings.
- Human testing has genuinely begun: a randomized placebo-controlled pilot in pre-frail adults and a completed Phase 1 in oncology.
- Collected without harm from tissue that would otherwise be discarded.
What's uncertain
- Large-scale human outcome data does not exist for either use.
- The foundational young-plasma evidence is from mice, and mouse-to-human is a long road.
- No cord blood plasma or AFP product is approved as a therapy by the FDA or EMA.
- Preparations vary between providers, and plasma products are defined by their processing.
Worth considering
- Ask how the plasma is collected, screened, processed, and stored; those steps are the product.
- Ask what specifically is in the preparation: whole plasma, a fraction, or isolated AFP.
- Expectations belong at early-trial level: promising biology, beginning evidence.
- Physician-directed use within a broader protocol is the setting these belong in.
Why the evidence lags the interest
Birth-tissue biologics are hard to patent and inexpensive to produce, which leaves no sponsor with a business case for the large trials that would settle the questions. The pilot studies that exist were run by academic groups. So the field advances on mechanism papers, animal work, and small first-in-human studies, while practice moves faster in jurisdictions that permit physician-directed use. Untested is not the same as tested and found wanting, and here almost everything of practical interest still sits in the untested column.
What the key studies tested
Our framing rule for evidence: a study tests one preparation, in one model or population, on defined endpoints. Where the evidence sits:
Preclinical & practice
The young-plasma cognition findings (mice), and most regenerative uses offered in practice.
Early trials
The pre-frail adults pilot (randomized, placebo-controlled) and the AFP-targeted cell therapy Phase 1 in liver cancer.
Late-stage trials
None.
Approved uses
None as a therapy.
And the studies that anchor the story:
- The 2014 Nature Medicine parabiosis study: joining the circulation of young and old mice reversed certain age-related cognitive impairments in the older animals, with measurable changes in the brain's memory circuitry. The founding document of the young-plasma idea, and an animal study.
- The Phase 1 pilot in pre-frail adults (NCT02418013): 64 participants, randomized, double-blind, placebo-controlled, testing cord blood and plasma against placebo with physical function and aging biomarkers as endpoints.
- The AFP-targeted Phase 1 (NCT03132792): patients' own T cells engineered to recognize AFP in advanced liver cancer, showing how AFP's biology is already being used in serious human research.
- The 2022 Trends in Immunology review: the definitive account of AFP as a selective immunomodulator rather than a blunt suppressant.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Is this the "young blood" thing from the headlines?
It is the scientifically serious end of that conversation. The headlines came from mouse studies where young circulation improved aging brains; cord blood plasma is the most practical human source of early-life circulating factors, collected harmlessly at birth. The mouse findings are real, the human evidence is a beginning pilot trial, and holding those two honestly apart is the whole game.
What makes AFP special?
Its immune behavior. Rather than suppressing immunity across the board, AFP appears to steer specific cell populations toward regulation, which is why reviewers discuss it for autoimmune conditions where balance is the goal. It is also a recognized target in liver cancer research, so its biology is being applied in human trials from two directions at once.
Are these treatments approved?
No. Neither cord blood plasma nor AFP is approved as a therapy by the FDA or EMA. They are used in regenerative protocols abroad under physician direction, and the human trial record is a handful of early studies. Expectations should be set accordingly, and any provider should be able to explain exactly what is in their preparation and how it was processed.
How is cord blood plasma different from the stem cells?
Same source, different fraction. Cord blood and tissue yield cells, including the MSCs covered elsewhere in this library, while the plasma is the cell-free liquid carrying proteins and signaling factors like AFP. The cells do signaling work of their own; the plasma is the signal soup itself. In practice the fractions are often used in combination within a protocol.
What to take away
If you remember five things from this article, make them these:
- Cord blood plasma carries the signaling chemistry of early life, and AFP is its best-characterized single factor.
- AFP regulates immunity selectively rather than suppressing it, which is why autoimmune and oncology researchers both study it.
- The young-plasma rationale rests on striking mouse findings; the human evidence is one careful pilot and counting.
- Nothing here is approved as a therapy, and the preparation details are the product: collection, screening, processing, storage.
- Cautious interest is the right posture: genuinely promising biology, genuinely early evidence, held together honestly.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Cord Blood Plasma & AFP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.